Results 101 to 110 of about 28,830 (248)

Proprotein Convertase Inhibition Results in Decreased Ski Proliferation, Tumorigenesis, and Metastasis

Neoplasia: An International Journal for Oncology Research, 2010
PACE4 is a proprotein convertase (PC) responsible for cleaving and activating proteins that contribute to enhance tumor progression. PACE4 overexpression significantly increased the susceptibility to carcinogenesis, leading to enhanced tumor cell ...
Daniel E. Bassi, Jirong Zhang, Jonathan Cenna, Samuel Litwin, Edna Cukierman, Andres J.P. Klein-Szanto   +5 more
doaj   +1 more source

Variant Prioritization by Pedigree‐Based Haplotyping

Genetic Epidemiology, Volume 50, Issue 3, April 2026.
ABSTRACT Whole genome sequence (WGS) data provides opportunities for comprehensive evaluation of variants that may influence complex traits. However, prioritizing the large number of variants, particularly those in non‐coding regions, is a challenge.
Rafael A. Nafikov, Harkirat K. Sohi, Alejandro Q. Nato Jr., Andrea R. Horimoto, Tyler R. C. Day, Thomas D. Bird, Anita L. DeStefano, Elizabeth E. Blue, Ellen M. Wijsman   +8 more
wiley   +1 more source

Biosynthesis and enzymology of the Caenorhabditis elegans cuticle: identification and characterization of a novel serine protease inhibitor. [PDF]

, 2006
The nematode Caenorhabditis elegans represents an excellent model in which to examine nematode gene expression and function. A completed genome, straightforward transgenesis, available mutants and practical genome-wide RNAi approaches provide an ...
Andrew J. Birnie, Antony P. Page, Brenner, Brooks, Canty, Chu, Davis, Edens, Eschenlauer, Frand, Friedman, Gillian McCormack, Hawdon, Hill, Johnstone, Kamath, Kamath, Kramerova, Kramerova, Kress, Lustigman, Milstone, Myllyharju, Myllyharju, Novelli, Page, Page, Page, Page, Page, Pappano, Peters, Poole, Roberts, Sapio, Simmer, Singh, Sulston, Thacker, Thacker, Thein, Winter, Yang   +42 more
core   +1 more source

Extracellular and Membrane Protein: Structure, Biological Functions, Diseases, and an Emerging Modality for Drug Discovery

MedComm, Volume 7, Issue 4, April 2026.
Targeted protein degradation represents a paradigm shift from traditional protein inhibition to complete protein elimination. This is achieved through three main strategies for degrading extracellular and membrane proteins: recruitment of cell‐surface LTRs, engagement of intracellular proteins, and receptor‐independent mechanisms.
Mengqing Zhao, Wenhao Yin, Jianjian Han, Huimin Wang, Zheng Liu, Lilong Liu, Wuxiang Mao   +6 more
wiley   +1 more source

Transport and equilibrium uptake of a peptide inhibitor of PACE4 into articular cartilage is dominated by electrostatic interactions [PDF]

, 2010
The availability of therapeutic molecules to targets within cartilage depends on transport through the avascular matrix. We studied equilibrium partitioning and non-equilibrium transport into cartilage of Pf-pep, a 760 Da positively charged peptide ...
Byun, Sangwon, Fok, Kam, Frank, Eliot, Grodzinsky, Alan J., Malfait, Anne-Marie, Tortorella, Micky D.   +5 more
core   +1 more source

Epigenetic mechanisms and therapeutic innovations in chronic pain‐associated neuropsychiatric co‐morbidities

British Journal of Pharmacology, Volume 183, Issue 7, Page 1313-1340, April 2026.
Abstract Chronic pain, marked by nociceptive sensitization and maladaptive neuroplasticity, affects 30% of the global population with escalating socioeconomic burdens. Epidemiological data show a 2‐3‐fold increase in neuropsychiatric co‐morbidities among individuals with chronic pain, where epigenetic dysregulation serves as a key mechanism linking ...
Kai Zhang, Sijia Zhu, Na Xing, Zhen Zhou, Jiayi Chen, Tianen Si, Mingrui Li, Lin Jia, Yousef Rastegar‐Kashkooli, Tom J. Wang, Wei Zhu, Jing Li, Chao Jiang, Junmin Wang, Moxin Wu, Xiaoping Yin, Weidong Zang, Jian Wang, Songxue Su   +18 more
wiley   +1 more source

Low-density lipoprotein cholesterol lowering therapies: what is on the horizon? [PDF]

, 2015
Elevated low-density lipoprotein cholesterol (LDL-C) levels are associated with an increased risk for cardiovascular disease (CVD). Statins have been the cornerstone of lipid therapy to lower LDL-C for the past two decades, but despite significant ...
Figueredo, M.D., Vincent M, Gadi, Ramprasad   +1 more
core   +1 more source

Variation in PCSK9 and HMGCR and Risk of Cardiovascular Disease and Diabetes [PDF]

, 2016
BACKGROUND: Pharmacologic inhibitors of proprotein convertase subtilisin-kexin type 9 (PCSK9) are being evaluated in clinical trials for the treatment of cardiovascular disease.
Brook, Robert, Catapano, Alberico L., Chapman, John, Davey Smith, George, Fazio, Sergio, Ference, Brian, Giugliano, Robert, Neff, David, Robinson, Jennifer, Sabatine, Marc S, Voros, Szilard   +10 more
core   +3 more sources

Proprotein convertase subtilisin kexin 9 inhibitors: Current status and future directions

Journal of Clinical and Preventive Cardiology, 2017
The discovery of proprotein convertase subtilisin kexin 9 (PCSK9) has considerably changed the therapeutic options in the field of lipid management. PCSK9 reduces low-density lipoprotein receptor (LDLR) recycling, leading to a decrease of LDL cholesterol
JPS Sawhney, Saurabh Bagga
doaj   +1 more source

Evaluation of evolocumab on saphenous vein graft patency following coronary artery bypass graft surgery in people living with and without diabetes in the NEWTON‐CABG CardioLink‐5 trial

Diabetes, Obesity and Metabolism, EarlyView.
Hwee Teoh, Subodh Verma, G. B. John Mancini, Adrian Quan, Michael Szarek, Randi Elituv, Meena Verma, Elizabeth Misner, Aishwarya Krishnaraj, Peter Jüni, Michael J. Koren, Stephen J. Nicholls, Deepak L. Bhatt, C. David Mazer, Lawrence A. Leiter   +14 more
wiley   +1 more source